Bristol-Myers Squibb Company (BMY)
Bristol Myers: Quality Fundamentals Suppressed By Interest Rates
Bristol Myers Squibb has solid fundamentals that have been clouded by the rise of interest rates. The company's revenue is at risk due to higher debt burdens and future patent expiry concerns, but recent acquisitions and cost-saving measures provide potential for growth. BMY stock is undervalued compared to its sector, with a potential upside of 29% and a fair value estimate of $48 per share.
The 7 Most Undervalued Under-$50 Stocks to Buy in June 2024
For many investors, especially those who are just building a portfolio, undervalued stocks under $50 hold significant appeal. Investors can start a significant position, in terms of shares owned, for a small investment.
Dividend Harvesting Portfolio Week 170: $17,000 Allocated, $1,515.47 In Projected Dividends
The Dividend Harvesting Portfolio generated over $100 of dividend income in May, with a return on invested capital of 14.14%. The portfolio's diversification helped stabilize market conditions, with a 1.45% growth in profitability despite market declines. Dividend income from various investment baskets, including equities, ETFs, REITs, CEFs, BDCs, and treasuries, contributes to portfolio growth.
Bristol Myers (BMY) Reports Positive Data on Breyanzi, Opdivo (Revised)
Bristol Myers (BMY) announces positive data from three studies evaluating CAR T cell therapy Breyanzi (liso-cel) and three updated analyses on studies evaluating Opdivo at ASCO.
Bristol Myers (BMY) Reports Positive Data on Breyanzi, Opdivo
Bristol Myers (BMY) announces positive data from three studies evaluating CAR T cell therapy Breyanzi (liso-cel) and three updated analyses on studies evaluating Opdivo at ASCO.
Bristol-Myers: Why I Am Buying More Of This Falling Knife, Yielding 5.84%
Bristol-Myers Squibb has experienced significant declines in its stock price, but I believe it has potential for future growth. The risks of investing in BMY include underperformance compared to the market and potential setbacks in its drug pipeline. I believe that BMY is undervalued compared to its peers, and I am adding to my position in the company.
Why Bristol Myers Squibb (BMY) Outpaced the Stock Market Today
Bristol Myers Squibb (BMY) closed the most recent trading day at $41.77, moving +1.65% from the previous trading session.
Earn An 'Embarrassing' Amount Of Cash Flow From These Contrarian Picks
Amazon CEO Andy Jassy highlights key traits for success in a career professional, including working hard, being can-do, and following through on commitments. There are different paths to success, and income investors can potentially achieve a high level of success by buying quality undervalued companies that pay dividends. In this article, I highlight high-yielding names in REITs, Energy, and Healthcare that I find attractive at present.
2 No-Brainer Dividend Stocks You Can Buy With $100 in June
Dividend-paying stocks tend to outperform their non-dividend-paying cousins. Bristol Myers Squibb is a leading pharmaceutical company that has raised its dividend payout for 15 consecutive years.
Bristol-Myers Squibb: Looking Beyond The One-Time Quarterly Loss
S&P 500 operating EPS growth was solid at 6.4% in Q1, but critics argue that excluding profits from top tech stocks shows less impressive growth. Bristol-Myers Squibb faces a soft growth outlook, but high expected free cash flow and steady sales suggest today's valuation is simply too low. With a dividend yield now near 6%, I outline key price levels to monitor in this beaten-down pharma stock.
Pre-surgery treatment with Bristol Myers combination therapy leads to better skin cancer outcomes
Treatment with Bristol Myers Squibb's immunotherapies Opdivo and Yervoy prior to surgery for patients whose skin cancer had spread to lymph nodes had better outcomes than those who did not get the drugs before node removal procedures, according to data from a late-stage trial released on Sunday.
Bristol Myers (BMY) Gets EC Nod for Opdivo Label Expansion
Bristol Myers' (BMY) Opdivo combination regimen receives the European Commission's approval for the first-line treatment of unresectable or metastatic urothelial carcinoma.
